Embarking on the next phase: Deals and data
e-Therapeutics (ETX) has appointed a new CEO, Dr Raymond Barlow, who will join the company by 1 May 2017. He brings significant R&D and business development experience, which will be invaluable in driving ETX to the next stage of its evolution. Following its 2016 strategic review, ETX’s near- to mid-term focus is on deriving value from its proprietary network pharmacology discovery platform. Potential deals from late 2017 would provide external validation for the platform and differentiated discovery approach, and generate revenues. Portfolio rationalisation secures ETX’s funding runway into early 2019; deal flow would extend this. Preclinical data on the five core discovery assets should stimulate interest from potential partners/collaborators. Deals and data are the next key catalysts.E-Therapeutics is a drug discovery company with a proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and utilizing public and proprietary chemical biology and multi-omics data. The therapeutic focus of Co.'s discovery activity is in areas of disease with unmet medical need, including immuno-oncology.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.